ALNY's revenue has compounded from roughly $594M in 2025Q1 to about $1.5B in 2026Q3, suggesting a shift toward recurring product sales, with gross margins holding near 75% to 88%.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue climbed from about $594M in 2025Q1 to roughly $1.5B in 2026Q3 with gross margins of 75% to 88%, but operating margin swung from -17.7% to 29.5%, indicating that gross profit strength has not yet translated into stable bottom-line results.
Alnylam Pharmaceuticals specializes in RNA interference (RNAi) therapeutics for genetically defined diseases, positioning it as a leader in this innovative biopharmaceutical field.
The company provides comprehensive investor resources, including financial filings, releases, and reports, facilitating informed investment decisions.
Detailed stock analysis, price targets, and earnings estimates for Alnylam Pharmaceuticals are readily available, aiding investors in evaluating the stock's potential.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | $16.26+879.5% vs $1.66 | $1.5B+1.9% vs $1.4B |
Q3 2026 Jul 30, 2026 | $1.21-25.8% vs $1.63 | $1.3B-2.4% vs $1.3B |
Q2 2026 Apr 30, 2026 | $1.51+73.2% vs $0.87 | $1.2B+4.6% vs $1.1B |
Q1 2026 Feb 12, 2026 | $0.82-29.3% vs $1.16 | $1.1B-4.5% vs $1.1B |
Consensus EPS estimates for 2026 and 2027 revised upward by an average of 6.0% and 4.3%, respectively, during the third quarter. Microsoft Corporation had one of its strongest quarterly stock performances since 1998. Snowflake's strong stock performance was driven by a third consecutive quarter of product revenue growth acceleration.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its Board of Directors has authorized a $1 billion share repurchase program and that the Company will transition to new commercial leadership as it enters its next phase of growth. "Today we announced two important decisions, both of which demonstrate our conviction in Alnylam's future," said Amy Schulman, Chair of Alnylam's Board of Directors. "Alnylam ha.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it will present new clinical and real-world data at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9 in Chicago, Illinois, and the International Symposium on Amyloidosis (ISA) 2026, taking place November 15-18 in Montevideo, Uruguay. The presentations add to the growing body of evidence demonstrating strength in RNAi.
Wall Street analysts are making bold moves this week, with dramatic target price cuts on some high-flying names and surprise upgrades on stocks that took a beating in October. Which calls deserve your attention before the market opens?
Benchmark ALNY against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alnylam Pharmaceuticals, Inc. (ALNY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $39.42 | $6.55B | -11.55 | 33.87% | -64.64% | -110.84% | — | |
| $58.16 | $8.19B | -26.06 | 23258.15% | -47.79% | -60.05% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — | |
| $254.19 | $100.86B | -39.19 | -39.23% | -110.46% | -37.62% | — |
Alnylam Pharmaceuticals, Inc. (ALNY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alnylam Pharmaceuticals, Inc. (ALNY) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
May 27, 2026·SEC
Get notified when ALNY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alnylam Pharmaceuticals, Inc. (ALNY) stock FAQ — growth, dividends, profitability & financials explained
Alnylam Pharmaceuticals, Inc. (ALNY) reported $5.01B in revenue over the trailing twelve months. Revenue was $3.71B in fiscal year 2025.
Alnylam Pharmaceuticals, Inc. (ALNY) grew revenue by 56.2% over the trailing twelve months, compared with the twelve months before.
Yes. Alnylam Pharmaceuticals, Inc. (ALNY) earned $2.72B in net income over the trailing twelve months (a 54.3% net margin).
Alnylam Pharmaceuticals, Inc. (ALNY) had a return on equity (ROE) of 159.7% over the trailing twelve months. That is well above the market's typical 10-15%.
Alnylam Pharmaceuticals, Inc. (ALNY) generated $500.7M in free cash flow over the trailing twelve months.
